Lichen planus
Also known as: Planus, Flat, Plano, Plani
Methodology & AI Transparency ⓘ
Lichen planus Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Lichen planus (also termed Planus or Flat)—coded clinically as L43.9 across Skin & Dermatology guidelines—combines dermoscopy or punch in Lichen planus (L43.9: biopsy when atypical) with structured follow-up of Affected Body Surface in Lichen planus (L43.9: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L43.9)).
- 2 Real-world patient consensus: Diagnostic registry L43.9: Lichen planus is managed within Skin & Dermatology (aka Planus).
- 3 Typical cash cost range: Clinicians assessing Lichen planus focus on cutaneous immune skewing in Lichen planus (L43.9: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Lichen planus: 25-Hydroxy Vitamin D in Lichen planus (L43.9: & hs-CRP) (25(OH)D 40–65 ng/mL (L43.9)) and Affected Body Surface in Lichen planus (L43.9: Area (BSA /).
Ask our AI Specialists anything about Lichen planus
What Is Lichen planus?
Lichen planus (also termed Planus or Flat)—coded clinically as L43.9 across Skin & Dermatology guidelines—combines dermoscopy or punch in Lichen planus (L43.9: biopsy when atypical) with structured follow-up of Affected Body Surface in Lichen planus (L43.9: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L43.9)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Lichen planus (ICD-10 L43.9) is driven by cutaneous immune skewing in Lichen planus (L43.9: (Th2/IL-4/IL-13 in atopic); specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor Affected Body Surface in Lichen planus (L43.9: Area (BSA /) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Lichen planus (L43.9): compromised epidermal barrier in Lichen planus (L43.9: with dryness, fissuring,)
- • Secondary Lichen planus clinical sign: post-inflammatory hyperpigmentation, facial in Lichen planus (L43.9: flushing, or pitted)
- • Symptom flares in Lichen planus correlating with 25-Hydroxy Vitamin D in Lichen planus (L43.9: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L43.9)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Lichen planus (L43.9: biopsy when atypical) evaluation (L43.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Lichen planus Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L43.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Lichen planus (L43.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (L43.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Lichen planus (L43.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L43.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Lichen planus (L43.9: ALT (if systemic) | Within baseline reference limits (L43.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Lichen planus
Treatment selection for Lichen planus depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lichen planus)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Skin-applied clobetasol propionate 0.025% oral gel in the treatment of oral The results suggest that applied to the skin clobetasol propionate 0.025% oral gel is more effective than placebo in improving disease severity (ODSS) and global change (GRC) in patients with symptomatic OLP. BMC oral health • 2026-05-20 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 42163196 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Ivarmacitinib in moderate-to-severe eczema patients with Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments. The Journal of dermatological treatment • 2025-12-15 • Phase III Randomized Trial | N = 132 | 88/100 | PMID 41288059 ↗ |
| What the Latest Evidence Really Says About Comorbidities Associated With Lichen LPP is significantly associated with autoimmune disorders, thyroid diseases, and skin cancer. International journal of dermatology • 2025-12-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 40579650 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical effectiveness of finasteride versus hydroxychloroquine in the treatment Both finasteride and hydroxychloroquine are equally effective, safe, and well-tolerable for treating FFA patients. Journal of cosmetic dermatology • 2024-02-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 37691183 ↗ |
Lichen planus Patient Community & “People Like Me” Threads
Filter Lichen planus community threads and patient logs by age, biological sex, dosage, and treatment duration.